Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.
Boogerd LSF, Boonstra MC, Prevoo HAJM, Handgraaf HJM, Kuppen PJK, van de Velde CJH, Fish A, Cordfunke RA, Valentijn ARPM, Terwisscha van Scheltinga AG, MacDonald GC, Cizeau J, Premsukh A, Vinkenburg van Slooten ML, Burggraaf J, Sier CFM, Vahrmeijer AL. Boogerd LSF, et al. Among authors: terwisscha van scheltinga ag. Surg Oncol. 2019 Mar;28:1-8. doi: 10.1016/j.suronc.2018.10.004. Epub 2018 Oct 23. Surg Oncol. 2019. PMID: 30851880
First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma.
de Valk KS, Deken MM, Handgraaf HJM, Bhairosingh SS, Bijlstra OD, van Esdonk MJ, Terwisscha van Scheltinga AGT, Valentijn ARPM, March TL, Vuijk J, Peeters KCMJ, Holman FA, Hilling DE, Mieog JSD, Frangioni JV, Burggraaf J, Vahrmeijer AL. de Valk KS, et al. Among authors: terwisscha van scheltinga agt. Clin Cancer Res. 2020 Aug 1;26(15):3990-3998. doi: 10.1158/1078-0432.CCR-19-4156. Epub 2020 Apr 28. Clin Cancer Res. 2020. PMID: 32345649 Clinical Trial.
A zwitterionic near-infrared fluorophore for real-time ureter identification during laparoscopic abdominopelvic surgery.
de Valk KS, Handgraaf HJ, Deken MM, Sibinga Mulder BG, Valentijn AR, Terwisscha van Scheltinga AG, Kuil J, van Esdonk MJ, Vuijk J, Bevers RF, Peeters KC, Holman FA, Frangioni JV, Burggraaf J, Vahrmeijer AL. de Valk KS, et al. Among authors: terwisscha van scheltinga ag. Nat Commun. 2019 Jul 16;10(1):3118. doi: 10.1038/s41467-019-11014-1. Nat Commun. 2019. PMID: 31311922 Free PMC article. Clinical Trial.
Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
Warnders FJ, Waaijer SJ, Pool M, Lub-de Hooge MN, Friedrich M, Terwisscha van Scheltinga AG, Deegen P, Stienen SK, Pieslor PC, Cheung HK, Kosterink JG, de Vries EG. Warnders FJ, et al. Among authors: terwisscha van scheltinga ag. J Nucl Med. 2016 May;57(5):812-7. doi: 10.2967/jnumed.115.168153. Epub 2016 Feb 4. J Nucl Med. 2016. PMID: 26848172 Free article.
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG. ter Weele EJ, et al. Among authors: terwisscha van scheltinga ag. Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877. Oncotarget. 2015. PMID: 26536664 Free PMC article.
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies.
Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schröder CP, Kosterink JG, Lub-de Hoog MN, de Vries EG. Terwisscha van Scheltinga AG, et al. Among authors: van dam gm. J Nucl Med. 2011 Nov;52(11):1778-85. doi: 10.2967/jnumed.111.092833. Epub 2011 Oct 11. J Nucl Med. 2011. PMID: 21990576 Free article.
In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hülsmeyer M, Nagengast WB, Schröder CP, Kosterink JG, de Vries EG, Audoly L, Olwill SA. Terwisscha van Scheltinga AG, et al. J Nucl Med. 2014 Apr;55(4):665-71. doi: 10.2967/jnumed.113.124941. Epub 2014 Mar 10. J Nucl Med. 2014. PMID: 24614223 Free article.
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment.
Pool M, Kol A, de Jong S, de Vries EGE, Lub-de Hooge MN, Terwisscha van Scheltinga AGT. Pool M, et al. Among authors: terwisscha van scheltinga agt. MAbs. 2017 Nov/Dec;9(8):1370-1378. doi: 10.1080/19420862.2017.1371382. Epub 2017 Sep 5. MAbs. 2017. PMID: 28873009 Free PMC article.
34 results